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A B S T R A C T
Proteinase 3 (PR3), together with other serine proteases, such as neutrophil elastase (NE) and cathepsin G (CG),
regulates inflammatory and immune responses. However, in comparison with NE and CG, there is increasing
evidence that PR3 functions significantly differ. In particular, PR3 can bind to cell membranes and such
membrane-bound PR3 (mbPR3) might be differently involved in the activation of cytokines, growth factors,
cellular receptors, and in the regulation of cell apoptosis. For instance, PR3 membrane binding can block some
“eat me” signals, notably, phosphatidylserine membrane lipid, and facilitate non-resolving inflammation. Based
on the clear evidence that PR3 membrane binding affects the biological functions of PR3, we designed pepti-
domimetic inhibitors that can remove mbPR3 from the membrane surface in vitro without influencing PR3
catalytic activity. Such inhibitors, which specifically target PR3 binding to membranes, are still lacking. In
particular, we found peptidomimetics that inhibit binding of PR3 to POPC:PS liposomes, which mimic the
biological environment of PR3.
1. Introduction
Over the last few years, many studies have focused on investigating
inflammatory and immune responses showing that the neutrophil
serine proteases, such as proteinase 3 (PR3), elastase (NE) and cathe-
psin G (CG) play significant roles in many such regulatory responses.
For instance, these proteases are massively released at the site of in-
flammation and responsible for tissue remodeling, cytokine activation
and degradation, and specific membrane-receptor stimulation. No
wonder that this multi-functionality involves PR3, NE and CG in pa-
thological conditions, such as chronic inflammation.
So far, it was discovered that one of these serine proteases - PR3 -
stands out from the others due to its specific membrane binding. For
example, the so-called constitutive membrane-bound PR3 (mbPR3)
constantly expresses on the surface of the quiescent neutrophils,
whereas NE and CG do not. This constitutive mbPR3 is enzymatically
inactive [1,2] but cannot be considered dormant as it can bind anti-
neutrophil cytoplasmic antibodies (ANCA) that stimulate neutrophil
activation and may lead to non-resolving inflammation [3,4]. Fur-
thermore, the neutrophils activated by ANCA or other proinflammatory
mediators secrete enzymatically active soluble PR3, NE, CG and so-
called induced mbPR3. Moreover, the activated neutrophils release
membrane-bound NE and CG [3,5,6]. However, it was shown that
mbPR3, mbNE and mbCG have different sensitivity to inhibitors [5],
apart from α1-proteinase inhibitor (A1PI) that clears and inhibits all of
them. For example, mbNE and mbCG are removed from the cell surface
by elafin (a natural protease inhibitor), whereas the mbPR3-elafin
complex remains bound to the membrane [3,7]. Therefore, the re-
sistance of mbPR3 to some naturally occurring inhibitors explains the
unique behavior of PR3, and also means that in diseases the levels of
PR3 are less efficiently controlled than the levels of other serine pro-
teases.
Additionally, the pathological conditions are frequently accom-
panied by the protease-antiprotease imbalance, where the proteases
overwhelm the antiproteases [5]. For example, people whose A1PI level
is below 35% are more prone to chronic obstructive pulmonary disease
(COPD) and vasculitis [8]. The A1PI deficiency may be a case of a ge-
netic disorder, which affects about 1 in 2000–5000 individuals [5]. The
treatment of concomitant diseases includes the infusion of purified
A1PI. In spite of the fact that the effectiveness of this cure is still not
confirmed, up to now it is the only available option so new therapeutics
are needed. Moreover, A1PI does not prevent ANCA binding to mbPR3
[9–13], and patients with high mbPR3 are more susceptible to a relapse
during vasculitis than patients with low concentrations of mbPR3 [3].
That is why it is necessary to design new effective and selective in-
hibitors of mbPR3. While efforts to design synthetic substrate-like
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inhibitors targeting the PR3 catalytic site are reviewed [5], inhibitors
that specifically target the PR3 binding to membranes are lacking. In
2018 we presented the pioneer D-peptide inhibitor of the PR3 mem-
brane-binding site [14]. Herein we describe a new broader set of D-
peptide inhibitors and confirm that they inhibit PR3 binding to various
types of membranes. These inhibitors may contribute to elucidating the
details of PR3 pathological roles and to future therapeutic approaches
in the treatment of inflammatory diseases.
2. Results and discussion
2.1. PR3 binds to anionic liposomes
In our previous work we showed that short D-peptides are able to
inhibit PR3 binding to neutral POPC liposomes [14]. Herein we in-
vestigated the interactions of PR3 with liposomes that contained the
most abundant anionic phospholipid – phosphatidylserine (PS) [15].
Recently, it was discovered that PR3 blocks PS and that the PR3-PS
interaction works as a “don't eat me” signal preventing the phagocytosis
[16]. Additionally, such ineffective phagocytosis and apoptotic cell
fragments that are not cleared may be theoretically the cause of ANCA,
which could enhance chronic inflammation [17]. Thus, the study and
inhibition of the PR3-binding to PS can further shed light on the PR3
pathological roles. Hereby, we formulated neutral POPC and anionic
POPC:PS, as well as PS liposomes, using freeze-thaw cycles and extru-
sion to assure unilamellarity and specific liposome size. The ratio of
POPC and PS in POPC:PS liposomes was 9 to 1 because phosphati-
dylserine accounts for about 10% of all phospholipids in mammalian
cells [18–20].
To estimate the PR3 binding to these liposomes, we used the bio-
layer interferometry (BLI). The BLItz interferometer measures the
change in optical thickness of the biological layer loaded on the ap-
propriate biosensor. Thus, we loaded a lipophilic aminopropylsilane
(APS) biosensor with the liposome solutions and detected the changes
of the bio-layer thickness upon PR3 binding as relative intensity units in
nm (Scheme 1 and Fig. S1). The estimated KD of PR3 binding to POPC
and POPC:PS liposomes was equal to 1.8×10−7 and 1.2×10−7M,
respectively. The KD of the PR3-POPC interaction agrees with the pre-
viously estimated one with the SPR technique (9.2× 10−7M) [21]. The
binding of PR3 to PS liposomes might be assessed as biphasic (Fig. S1).
First, the association curve rose steeply, and then continued to rise at a
slower pace without reaching equilibrium. For such non-ideal beha-
viors, curve fitting and determination of binding parameters would be
unreliable and is thus not presented.
To illustrate the PR3 preference for certain liposomes, we present
the data of the binding signal at 1 μM of PR3 (Fig. 1). We chose this
concentration as the safest checking point for all liposomes on the APS
biosensor. Higher concentrations of PR3 gave a distorted signal, which
could result from significant non-specific binding or aggregation (Fig.
S1). Fig. 1 shows that PR3 binds to all liposomes, but prefers the anionic
PS liposomes.
The fact that PR3 interacts with PS lipids has already been estab-
lished [6,16]. However, herein we present the first quantitative results
for PR3 binding to mixed POPC:PS liposomes including the determi-
nation of dissociation constant KD. Moreover, previous studies have
proven that the PR3 loops carrying hydrophobic amino acids (V163,
F165, F166, I217, W218, T221, L223, F224) and basic amino acids
(R177, R186A, R186B, K187 and R222) are essential for the PR3
binding to liposomes (Fig. 2) [6,16,22,23]. Thus, the PR3 preference for
Scheme 1. A. Schematic representation of steps in a BLItz experiment. B. Changes of the bio-layer thickness in each step shown in A. C. The results of the PR3 binding
to POPC:PS liposomes. Only the PR3 association and dissociation steps (4 and 5 of B) are shown.
Fig. 1. The BLItz binding signal of 1 μM PR3 loaded onto various liposomes.
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the anionic liposomes, the information about hot spots for PR3 mem-
brane anchoring, as well as the discovered inhibitors of the PR3-POPC
interaction presented in our previous work [14] guided us to design
new potential inhibitors.
2.2. Peptides as potential inhibitors of the PR3-membrane binding
We have previously found that D-peptides inhibit PR3 binding to
POPC liposomes [14]. Following this idea, we have designed and syn-
thesized four new D-peptides, that we named DFFD, DFFK, EFFK and
DFFKL, and tested their potential as inhibitors of PR3 binding to lipo-
somes (Tables 1 and S1).
Note, that in our previous work [14] only one D-peptide
(Nter-SAKEAFFKLLAS-Cter named as D-SAK-12) inhibited PR3 binding
to liposomes, and only POPC liposomes were considered. Until now it
was the only one known D-peptide sequence that targets the membrane-
binding site of PR3. Additionally, we recorded that another peptide
(Nter-KFFKFFKFFK-Cter named as D-(KFF)3K) significantly decreased
the binding of PR3 to POPC liposomes but also itself bound with high
affinity to the liposomes. Since we consider binding of the PR3-mem-
brane inhibitor to the cell membrane alone as undesired, this D-peptide
had to be modified to suppress its binding to liposomes. That is why,
based on D-(KFF)3K, we synthesized four new D-peptides DFFD, DFFK,
EFFK and DFFKL. In all new peptides we kept phenylalanine residues
because hydrophobic amino acids are essential for the PR3 binding to
liposomes (Fig. 2).
The DFFD peptide is the analogue of D-(KFF)3K, in which we
replaced all cationic lysines by anionic aspartic acids. Since the surface
of biological membranes contains anionic lipid headgroups, the cationic
residues of an inhibitor may, via peptide-lipid interactions, anchor PR3
to the membrane instead of causing its release. Moreover, as it was
mentioned above, basic amino acids of PR3 (R177, R186A, R186B,
K187 and R222) are the PR3 hot spots responsible for its binding to
membranes. That is why some anionic residues in inhibitor sequences
could promote peptide binding to PR3 (Fig. 2). Furthermore, in our
previous work, we discovered that one lysine in the peptide sequence
can anchor the potential inhibitor into the membrane binding site of
PR3. The inset of Fig. 2 shows the formed salt bridge between the lysine
K3 of D-SAK-12 and aspartic acid D226 of PR3 [14]. That is why in the
DFFK peptide we left one lysine, which could anchor the peptide into
the PR3 membrane-binding site by the salt bridge with D226 of PR3.
Moreover, in our previous molecular dynamics simulations, we de-
tected the interaction of glutamic acid E1 of D-SAK-12 with R222 of
PR3 (Fig. 2) [14]. Thus, in the EFFK peptide we substituted the aspartic
acid residues by glutamic acids. For the DFFKL peptide, we additionally
included leucine because molecular dynamics data suggested that it
should enhance binding of peptides to PR3 [14]. Thus, we stepwise
increased the complexity of the peptide sequences. All peptides were
synthesized as D-PEPTIDES to compare with our previous work [14] and
avoid possible proteolysis, as well as penetration into the membranes.
Additionally, four labeled peptides were synthesized (Table 1 and
S1). ba-DFFD, ba-DFFK, ba-EFFK and ba-DFFKL are identical to DFFD,
DFFK, EFFK and DFFKL, respectively, with additional a - 6-amino-
hexanoic acid (Ahx) linker and b - biotin label. All peptidomimetics
with or without label-groups were synthesized manually by the Fmoc
solid-phase peptide synthesis and used in further experiments as hy-
drochlorides (see Methods).
2.3. Three out of four peptides bind to PR3
We assessed further the binding affinity of the synthesized D-pep-
tides to PR3. To spare PR3, we used BLItz bio-layer interferometry.
Note, that BLItz requires only small quantities of PR3 (~4 μL of 1 μM
solution for one experiment), whereas, for example, the isothermal ti-
tration calorimetry (ITC) technique needs millimolar PR3 concentra-
tions in a minimum of 250 μL volume to assay the PR3-peptide binding.
We chose the biotin - streptavidin strategy, where the biotinylated
peptides were bound at a streptavidin biosensor (Scheme S1).
The peptides had been biotinylated at the last step of the Fmoc
solid-phase peptide synthesis (Tables 1 and S1). Moreover, we added
aminohexanoic linker to minimize steric effects. Thus, we loaded the
Fig. 2. A. Representation of PR3 highlighting amino acids forming the catalytic PR3 site (yellow) and the protein-membrane binding site (blue - hydrophobic and
green - cationic residues). B. Representation of PR3 binding mode with the D-SAK-12 D-peptide (Nter-SAKEAFFKLLAS-Cter).
Table 1
Sequences of D-peptides designed and tested in this study. Ahx stands for 6-
aminohexanoic acid linker.
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biosensors by peptides ba-DFFD, ba-DFFK, ba-EFFK and ba-DFFKL,
which are the labeled analogues of the DFFD, DFFK, EFFK and DFFKL
peptides, respectively. Next, we analyzed the PR3 association and dis-
sociation at different PR3 concentrations (Scheme S1, Fig. 3). We found
that PR3 bound to ba-DFFD, ba-DFFK and ba-EFFK with KD equal to
1.0, 1.12 and 2.9 μM, respectively. We did not detect any interaction of
PR3 with ba-DFFKL. These results indicated that leucine and glutamic
acid at positions 5 and 6 in the D-peptide sequence negatively influ-
enced the peptide-PR3 binding and this fact has to be considered in
further modifications.
2.4. The designed peptides do not affect the catalytic activity of PR3
PR3 is a multi-functional enzyme and is involved in many vital
processes, not only in pathological inflammation that we focused on.
For instance, PR3 activates and degrades cytokines and some mem-
brane receptors [1,24]. It is important to distinguish between the in-
hibition of the PR3 catalytic activity and inhibition of its membrane
binding (Fig. 2). Both types of inhibitors are needed and may be used to
address different functional aspects of the enzyme.
As mentioned above, ITC is a technique to estimate thermodynamic
parameters of association of non-labeled molecules, but ITC requires
millimolar amounts of reagents to study binding [25]. However, this
technique also suits perfectly to assay the catalytic activity, requiring
only nanomolar amounts of an enzyme. The ITC technique to determine
enzymatic activity was described by us in previous works and the de-
tails of the approach can be found in [26,27]. Thus, herein we used ITC
to monitor the heat change upon the PR3-catalyzed hydrolysis of β-
casein. We chose β-casein as a macromolecular substrate (~24 kDa)
since cytokines are proteins of similar size (~5–20 kDa). The ITC
thermograms indicated no influence of D-peptides on the catalytic ac-
tivity of PR3, whereas A1PI fully inhibited the hydrolysis of β-casein by
PR3 (Fig. S2). Moreover, we performed the microplate fluorescence
assay to confirm that the hydrolysis of the fluorogenic PKS301 substrate
is not inhibited by D-peptides (Figs. S3 and S4). The product emission
was on the same level both for PR3 alone and for PR3 pre-incubated
with D-peptides at different concentrations. Therefore, both assays
suggested that D-peptides do not interfere with the PR3 catalysis, which
was our requirement for the designed herein PR3 membrane inhibitors.
2.5. The peptides affect PR3 binding to POPC:PS liposomes loaded on a
hydrophobic APS biosensor
In the next step, we examined if D-peptides inhibit PR3 binding to
liposomes. The APS biosensor loaded with the liposomes was dipped
into the solutions of either PR3 alone or PR3 pre-incubated with D-
peptides. We observed that D-peptides significantly affect the binding of
PR3 to POPC:PS anionic liposomes (Fig. 4). Contrary, inhibition of PR3
binding to the neutral POPC liposomes was negligible (Fig. S5).
For the POPC:PS liposomes, the results of the A1PI control corro-
borated with a known fact that A1PI clears PR3 from the membranes
(Fig. 4). Moreover, the high signal for D-(KFF)3K proved that lysines
enhanced peptide binding to the anionic liposomes (Fig. 4). The or-
dering of the inhibition, from the strongest to the weakest, was as fol-
lows: EFFK > DFFKL > DFFD > DFFK. DKFF worked the worst,
which could be because the DFFK lysine in the complex with PR3 did
not play the expected role of an anchor (Fig. 2), but instead turned
toward the liposome side and held the peptide-PR3 complex at the li-
posomes. This suggestion could also explain effective inhibition by
EFFK, whose longer glutamic acid side chains could prevent the lysine-
liposome binding. Surprisingly, while our results described in subsec-
tion 2.3 show no PR3 binding to biotinylated DFFKL on the streptavidin
biosensor (Fig. 3), this peptide, as well as its biotin-labeled analogue,
ba-DFFKL, inhibited PR3 binding to the liposomes loaded on the APS
biosensor (Fig. 4). As we suggested the attachment of the biotin-labeled
peptides to the support (Scheme S1), and therefore, the restriction of
the peptide mobility might significantly affect the peptide-PR3 binding.
Moreover, the results of the peptide action at the liposome loaded on
APS showed that the labeled peptides inhibit the PR3 binding in the
following order: ba-DFFD > ba-DFFK > ba-DFFKL > ba-EFFK,
which is different from unlabeled peptides. This is yet another con-
firmation that the labels, in spite of their value as technical help to
perform experiments, might affect binding and they misrepresent their
non-labeled analogues.
Further quantification of the inhibition by measuring the effect for
different peptide concentrations was not successful. In this assay, we
could not increase peptide concentrations above 10 μM due to high
signals from D-peptide binding to the liposomes (Fig. S6). For example,
the binding signal for 10 μM DFFD at POPC:PS liposomes was equal to
0.1 nm, whereas the binding signal for 20 μM DFFD increased up to
0.7 nm. Additionally, dissociation signals for the peptides, PR3, and
PR3-peptide complexes from the liposomes were incomplete and looked
rather as a plateau than a decline to the initial baseline (Scheme 1C and
Fig. S7). We explain this as unsteady binding of the liposomes on the
APS biosensor and amplified non-specific binding. Thus, the solution
seemed to be to control and regulate the liposome binding. That is why,
Fig. 3. The BLItz data for the PR3 binding to the biotinylated D-peptides loaded
on the streptavidin biosensor presented as the height of the binding signal in nm
at 189 s time point (the last seconds of the association step).
Fig. 4. The results of the BLItz experiments on POPC:PS liposomes loaded onto
the APS biosensor (the binding in nm at 128 s time point of the association
step). 1 μM of PR3 alone or pre-incubated with 2 μM of A1PI or 10 μM of the D-
peptides. The statistical significance of the differences between PR3 and tested
samples was determined by ANOVA test and is equal to P < 0.0001 for all
peptides, except for D-(KFF)3K where the difference was not significant.
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in the next step, we used the streptavidin strategy to verify and support
the above data of the PR3-liposome binding inhibition by the designed
D-peptides.
2.6. The peptides affect PR3 binding to the POPC:PS biotin-labeled
liposomes loaded on a streptavidin biosensor
To resolve the above mentioned issues, we changed the strategy and
used biotinylated lipids, which were tightly attached to a streptavidin
biosensor. We formulated the POPC:PS vesicles with the biotinylated
lipid DSPE-PEG(2000)-biotin [28,29], where a long polyethylene glycol
(PEG2000) spacer distanced the liposomes from the biosensor surface
(Fig. S8 and Scheme 2). Supression of non-specific binding was further
assured by biocytin and BSA (Scheme 2).
The peptides dissociated fully from the attached liposomes (Scheme
2B – dashed lines, Figs. S7 and S9). The observed peptide association
signals, along with their fast and full dissociation from liposomes,
suggest non-specific peptide-liposome binding. On the contrary, PR3
did not fully dissociate from the POPC:PS surface due to the PR3 an-
choring in the liposomes (Scheme 2B, Fig. S7). The above observations
suggest that in spite of the observed decrease in the association signal
for the PR3 pre-incubated with the peptides, the association steps
cannot be treated as quantitative due to D-peptide interactions with the
liposomes. Such non-specific peptide binding to liposomes could mis-
lead data analysis, particularly for higher concentrations of the pep-
tides, as well as for experiments on hydrophobic biosensors such as
APS. This is why we suggest focusing on the dissociation step only.
We first checked if the PR3 binding to POPC:PS liposomes is in-
hibited by the control A1PI (Fig. S9A). The binding signals for PR3 in
the complex with A1PI (at 1.7 and 3.4 μM) were below the signal for
PR3 alone, but they were not concentration dependent. Moreover, the
higher A1PI concentration of 6.8 μM increased the binding signal above
the control PR3 one, which may happen due to the imposed A1PI
binding signal (data not shown). Thus, the assessment of the association
step could be incorrect. On the contrary, the dissociation step is in-
formative: for the A1PI/PR3 complex dissociation practically decreased
to zero, which confirmed PR3 clearance from the liposome surface by
A1PI.
The positively charged D-SAK-12, at 20 μM, showed significant
binding to POPC:PS liposomes (Fig. S9B, orange dashed line). Pre-in-
cubation of PR3 with higher D-SAK-12 concentrations decreased the
association signal slightly and to one similar level, which can be ex-
plained by D-SAK-12 binding to liposomes. However, the dissociation
step for the peptide-PR3 complex decreased with increasing inhibitor
concentrations: the more peptide we had, the faster PR3 dissociated
from the liposomes (Figs. 5 and S9B).
The DFFD peptide, which does not have cationic residues, bound to
POPC:PS liposomes least effectively (with the lowest association
Scheme 2. A. Schematic representation of the BLItz experiment for the streptavidin biosensor loaded with the biotinylated liposomes. B. The results of the PR3 (red
line), PR3-DFFD complex and DFFD alone (dashed lines) binding to biotinylated POPC:PS liposomes. The association and dissociation steps are shown.
Fig. 5. The dissociation points (in nm at 435 s time point) for 2.5 μM PR3 alone
or pre-incubated with D-peptides at different concentrations measured for the
POPC:PS liposomes.
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signal), as compared to the other peptides (Fig. S9C, dashed lines). A
considerable binding signal appeared only at 40 μM peptide con-
centration. DFFD/PR3 dissociation depended on the peptide con-
centration (Figs. 5 and S9C).
The DFFK peptide has a net charge of -2e, but contains one lysine,
which explains that already at 2.5 μM concentration this peptide bound
to the liposomes (Fig. S9D). For DFFK pre-incubated with PR3, the
association decreased relative to the control PR3 (up to 10 μM of
DFFK). However, higher peptide concentrations enhanced the signal,
likely due to the peptide-liposome binding. The dissociation step was
concentration dependent for all peptide concentrations (Figs. 5 and
S9D).
Binding of the negatively charged EFFK peptide was notable at
peptide concentration of 10 μM, higher as compared to DFFK. This can
be due to the length of the side chains of anionic residues. The asso-
ciation significantly decreased relative to the control (Fig. S9E). The
dissociation step showed that PR3 dissociated till the zero point in the
presence of the peptide (Fig. 5 and S9E).
The DFFKL peptide bears a net charge of -1e. At 20 μM concentra-
tion, this peptide gave significant binding signal to the liposomes (Fig.
S9F). The dissociation step showed that PR3 was cleared by DFFKL
(Figs. 5 and S9F).
The binding signals, in nm, at the last seconds of the dissociation
steps, for each peptide concentration are presented in Fig. 5. Most
peptides clear PR3 from the POPC:PS liposomes more effectively than
the previous D-SAK-12 peptide. However, we would like to emphasize
that due to possible technical issues, such as non-specific binding and
label influence, these data may be only treated as qualitative. Never-
theless, all designed D-peptides turned out more efficient in inhibiting
the PR3 binding to liposomes than the pioneer inhibitor D-SAK-12 [14].
3. Materials and methods
3.1. Reagents
PR3 was purchased from Athens Research & Technology and all
other chemicals from Sigma Aldrich. 34.5 μM PR3 stock solution was
prepared in 50 mM MES buffer at pH 4.5 with 700 mM NaCl and 0.05%
Igepal and stored at −80 °C. 1mM peptide stock solutions were freshly
prepared in the running buffers. 1 mM α1-antitrypsin from human
plasma (A1PI) stock solution was prepared in 0.01% sodium azide and
stored at −80 °C. 1 mM β-casein solution was prepared in 50mM MES
buffer at pH 7.5 with 700mM NaCl and 0.05% Igepal.
3.2. Synthesis of D-peptides
All D-peptides were synthesized by the solid-phase method using
Fmoc-chemistry. Fmoc-AA-Wang resin (200–400 mesh, 0.65–0.71
mmol/g loading) was used as a solid support. All synthesis steps were
performed under Argon. Briefly, 100mg of Fmoc-AA-Wang resin was
swelled in 4 mL of DMF for 20 min. Then Fmoc-deprotection step was
performed by 4 mL of 20% piperidine in DMF, 3 times for 15 mins, and
the resin was washed by DMF. Then 3 eq. of the following: Fmoc-AA-
COOH, Fmoc-aminocaproic acid or biotin-ONp, were coupled by 3 eq.
of HATU, 3 eq. of HOAt and 5 eq. of DIPEA. The reaction mixture was
stirred for 2 h at room temperature under Argon. The coupling reaction
was repeated one more time in the same manner. Next, the reaction
mixture was washed by DMF. After completing the synthesis, the pep-
tides were cleaved from the resin and protecting groups (Boc, tBu) were
removed using the TFA/DCM/m-cresol mixture (85/10/5 (v/v/v)) and
stirring the reaction mixture for 2 h. The final solution was filtered to
cold ether. The precipitate from ether was centrifuged and washed by
ether. The purity of the peptides was checked on a reverse-phase HPLC
SYKAM equipped with a KNAUER C18 column (8× 250mm) and a
UV–Vis detector. A linear gradient from 20 to 70% water:acetonitrile
with 0.05% TFA within 30 min at flow rate 4 mL/min was applied.
Analyzed D-peptides were monitored at 210 nm. The collected fractions
were lyophilized. Then TFA/HCl exchange was carried out. The pep-
tides were dissolved in 100mM HCl, kept at room temperature for 1
min, and lyophilized. The purities of the synthesized peptides were
confirmed by HPLC and mass-spectroscopy (Tables 1 and S1, the mass-
spectra and HPLC-chromatograms are shown in Supporting informa-
tion).
3.3. Bio-layer interferometry
The bio-layer interferometry experiments were performed with the
BLItz system (Pall ForteBio LLC) in 10mM HEPES buffer (150 mM
NaCl, pH 7.4) at 25 °C. All experiments were triplicated and the average
signals from the association and dissociation steps are presented.
3.3.1. Preparation of liposomes
POPC and PS lipids were dissolved in chloroform to 10 mg/mL at
25 °C. The required amount of the stock solution was replaced to a glass
corex tube and deposited as a thin film by drying under the flow of
nitrogen for 3 h. Dried lipids were resuspended in 10 mM HEPES,
150mM NaCl, pH 7.4 to give a final lipid concentration of 1 mM POPC,
POPC:PS (9:1) or PS, and shaken overnight at 37 °C. For 1mM
POPC:PS:DSPE-PEG(2000)-biotin (9:1:0.3) liposomes, the required
amount of 1mg/mL DSPE-PEG(2000)-biotin solution in distilled water
was added. The lipid suspension was subjected to seven freeze-thaw
cycles using liquid nitrogen and a water bath. The hydrated multi-la-
mellar structures were then passed 10 times through a 100 nm poly-
carbonate filter using an extrusion apparatus (mini-extruder of Avanti
Polar Lipids) till a translucent solution.
3.3.2. PR3 binding to liposomes, aminopropylsilane biosensor – liposomes –
PR3
To check if PR3 binds to the liposomes, the 1mM POPC, POPC:PS
(9:1) or PS liposome solutions were uploaded on an aminopropylsilane
biosensor. Next, the loaded biosensor was dipped into PR3 solutions at
different concentrations (see Scheme 1). Detailed description is as fol-
lows: i. Baseline was recorded in the buffer (30 s). ii. 1 mM liposomes in
the buffer were loaded on the biosensor (120 s). iii. The buffer solution
of 0.1 mg/mL BSA was loaded (30 s). iv. PR3 solutions at different
concentrations in 0.1mg/mL BSA buffer solution were associated (120
s). v. The dissociation step in 0.1 mg/mL BSA buffer solution was run
(180 s). vi. The biosensor was regenerated by 40mM OG buffer solution
(30 s). vii. The baseline was recorded in the buffer (60 s). The asso-
ciation and dissociation steps at different PR3 concentrations are pre-
sented in Fig. S1. The data were analyzed by the BLItz software.
3.3.3. Inhibition of PR3 binding to liposomes, aminopropylsilane biosensor
– liposomes – PR3/peptide
To check if D-peptides inhibit the PR3 binding to liposomes, 1 mM
POPC, POPC:PS (9:1) or PS liposome solutions were uploaded on an
aminopropylsilane biosensor. Next, the loaded biosensor was dipped
into 1 μM PR3 solutions pre-incubated with buffer, 2 μM of A1PI, 20 μM
or 10 μM of D-peptide (Figs. 4, S5 and S6). The steps of the assay were
the same as for the PR3 binding to liposomes described above.
3.3.4. PR3 binding to peptides, streptavidin biosensor – biotinylated peptide
– PR3
To check if PR3 binds to the peptides, 20 μM biotinylated peptides
were uploaded on a streptavidin biosensor. Next, the biosensor was
dipped into the PR3 solutions (Scheme S1). Detailed description is as
follows: i. Baseline was recorded in the buffer (30 s). ii. 20 μM of bio-
tinylated peptide or 10 μg/L of biocytin solution in 0.1% BSA and
0.02% Igepal buffer solution were loaded on the streptavidin biosensor
(150 s for the first loading, 30 s in all next experiments). iii. 10 μg/L of
biocytin in 0.1% BSA and 0.02% Igepal buffer solution was loaded
(15 s). iv. The baseline was recorded in 0.1% BSA and 0.02% Igepal
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buffer solution (15 s). v. PR3 solutions at different concentrations in
0.1% BSA and 0.02% Igepal buffer solution were associated (100 s). vi.
The dissociation step in 0.1% BSA and 0.02% Igepal buffer solution was
run (180 s). vii. The biosensor was regenerated by 10mM glycine so-
lution in the buffer (120 s). viii. The baseline was recorded in the buffer
(120 s). The association and dissociation steps at different PR3 con-
centrations are presented in Scheme S1. Note that PR3 binds to biocytin
(up to 0.5 nm at the highest PR3 concentration). This background
binding signal was subtracted from all experiments. The data were
analyzed by the BLItz software (Fig. 3).
3.3.5. Peptide inhibition of PR3 binding to biotinylated liposomes,
streptavidin biosensor – liposomes – PR3/peptide
To check if peptides inhibit the PR3 binding to biotinylated lipo-
somes, the 1 mM POPC:PS:DSPE-PEG(2000)-biotin liposome solution
was uploaded on the streptavidin biosensor. Then the loaded biosensor
was dipped into 1 μM of PR3 pre-incubated with buffer or the peptides
at different concentrations (Scheme 2, Figs. 5 and S9). The steps of the
assay were the same as for the PR3 binding to peptides described above.
3.4. Isothermal titration calorimetry
ITC assays were carried out on Nano ITC (TA Instruments, New
Castle, DE, USA). The stirring speed in the calorimeter cell was
350 rpm. The composition of the buffer solution for the assay experi-
ments was identical for the substrates and enzyme, with or without the
inhibitors. Experiments were performed in MES buffer at 37 °C. 115 nM
PR3 solutions without inhibitors, with 1 μM A1PI or 100 μM peptide
inhibitors were pre-incubated at 37 °C for 30min. Next, twenty aliquots
of 2.5 μL of 1mM β-casein solution were injected every 150 s (Fig. S2).
In each experiment, the control injections of the substrate to the buffer
and the buffer to the enzyme were carried out, to eliminate the heat of
dilution.
3.5. Fluorescence assay
Fluorescence was measured on a microplate reader (Molecular
Device). The excitation wavelength was 355 nm and the emission wa-
velength 460 nm. Fluorescence experiments were performed in 10mM
HEPES buffer (150mM NaCl, pH 7.4) at 37 °C in the volume of 100 μL
per well. 2 nM PR3 solutions without or with different concentrations of
D-peptide inhibitors were pre-incubated at 37 °C for 10min before
adding the fluorogenic PKS301 substrate [30]. The PKS301 substrate
sequence is Ac-Glu(OBzl)-Lys(Ac)-Hyp(Bzl)-Nva-ACC, where ACC is 7-
amino-4-carbamoylmethylcoumarin. This substrate was added as seri-
ally diluted solutions for the kinetic experiment or as 50 μM solution in
the buffer for the inhibition experiments. The fluorescence data were
fitted using GraphPad. All experiments were performed as independent
triplicates. The averages with their standard deviations are shown as
results.
4. Conclusions
We investigated the binding of PR3 to various liposomes and, for the
first time, have determined the equilibrium dissociation constant for
PR3 binding to anionic mixed POPC:PS liposomes
(KD= 1.2×10−7M). The results confirmed that PR3 binds to neutral
POPC, as well as POPC:PS and PS anionic liposomes, with a preference
for the PS liposomes. This fact supports our knowledge of PR3 biolo-
gical actions; for example, PR3 can be attracted by externalized PS
during apoptosis and aggravate inflammation in the pathological si-
tuation of protease-antiprotease imbalance. That is why we focused on
the inhibition of this potentially destructive PR3 binding, specifically to
POPC:PS liposomes.
We designed four D-peptides, termed DFFD, DFFK, EFFK and
DFFKL and their biotin-labeled analogues ba-DFFD, ba-DFFK, ba-EFFK
and ba-DFFKL. The labeled peptide analogues were used to determine
the PR3-peptide interaction. We found that PR3 bound all peptides,
except the labeled ba-DFFKL, suggesting that leucine and glutamic acid
at positions 5 and 6 in the peptide sequence influence the peptide
binding to PR3. Thus, amino acid compositions at these positions have
to be re-evaluated in future modifications, probably by considering
hydrophobic combinations.
Moreover, we found that labeling and restriction of peptide mobility
affect the binding and misrepresent the non-labeled analogues. We
suggest avoiding labels and using non-labeled techniques, for example,
bio-layer interferometry, isothermal titration calorimetry, and surface
plasmon resonance spectroscopy. Nevertheless, in spite of unobserved
binding of one labeled peptide to PR3, further experiments confirmed
inhibition of the PR3 binding and clearance of PR3 from POPC:PS li-
posomes by all labeled and non-labeled peptides, as well as by control
A1PI. Furthermore, since we observed that lysines enhanced D-peptide
binding to the anionic liposomes, their number in peptide sequences
has to be limited. The glutamic acid residues, instead of aspartic ones,
were favorable due to their longer side chain and reduced peptide-li-
posome binding. We found that the most important point is to control
the amino acid position in the peptide; for example, lysines might not
play the expected role of an anchor in the PR3 interfacial binding site,
and instead contribute to holding the peptide-PR3 complex at the li-
posomes. That is why, for further modifications, we suggest stabilizing
the peptidomimetic structures by disulfide formation, olefin metathesis
or salt bridges between residues in peptide chains.
Overall, the presented peptidomimetic inhibitors efficiently remove
mbPR3 from the liposomes that mimic the cell surface, without influ-
encing the PR3 catalytic activity. Thus, these D-peptides can be further
modified to develop potential therapeutics for control of pathogenic
roles of PR3 in inflammation.
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